-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, WuXi Junuo announced that the clinical trial application of Ruikiolanza injection for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has been approved.
Ruiki Orenza Injection (trade name: Benoda) is a CD19-targeting drug independently developed by WuXi Ju Nuo on the basis of the CAR-T cell technology platform of Ju Nuo Medical, a subsidiary of Bristol-Myers Squibb (BMS).
At present, WuXi Junuo is still exploring the efficacy of Ruiki Aurenzai Injection in the treatment of more indications
It is reported that the approval of Ruikiolenza injection is a phase 1 open-label, single-arm, dose-escalating study (JWCAR029-006 study) in China, which aims to evaluate the drug in the treatment of r/r B- Safety, tolerability, pharmacokinetics, and determination of phase 2 recommended dose (RP2D) in children and young adult subjects with ALL
Published data show that B-ALL is the most common malignant tumor in children, and resistance to chemotherapy drugs usually leads to relapse or disease progression in patients, and patients after relapse often have a very poor survival rate
References:
[1] WuXi Junuo Announces Approval of Clinical Trial Application of Benoda® for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Children and Young Adults.
